NCT01322594View on ClinicalTrials.gov

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BIOLOGICAL

MEDI2338

MEDI2338 single intravenous (IV) dose (lowest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (highest dose)

OTHER

Placebo

Placebo single IV dose

Trial Locations (4)

6045

Research Site, Port Elizabeth

6529

Research Site, George

9300

Research Site, Bloemfontein

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY